The ICH E9(R1) Addendum on Estimands and Sensitivity Analysis provides a framework for defining the treatment effect a trial intends to estimate—the estimand. The addendum is widely adopted in ...
The Inflammatory burden Index (IBI) is an effective predictor for a range of malignancies. However, the significance of IBI in esophageal squamous cell carcinoma (ESCC) needs to be further verified.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results